Business Context and Reporting Period
PDS Biotechnology Corp (PDSB) filed a Form 8-K on September 7, 2026, reporting the entry into a Material Definitive Agreement. The Company, a Delaware corporation focused on biotechnology, announced a private placement of equity securities to raise capital for working capital, debt repayment, and clinical development.
Key Financial Metrics and Transaction Details
- Initial Closing Proceeds: Approximately $11,550,000 in aggregate gross proceeds expected.
- Securities Issued (Initial):
- Private Placement Shares: 20,875,220 shares.
- Pre-Funded Warrants: 20,009,736 warrants.
- Common Warrants: 20,442,479 warrants.
- Pricing:
- Share Unit Purchase Price: $0.2825 per unit (one share + one-half warrant).
- Pre-Funded Unit Purchase Price: $0.28217 per unit.
- Common Warrant Exercise Price: $0.22 per share.
- Pre-Funded Warrant Exercise Price: $0.00033 per share.
- Contingent Milestone Closing: Potential additional $11,000,000 ($10M from Nant Capital, $1M from AB Group) upon submission of a Phase 3 clinical trial protocol for PDS0301.
- Maximum Dilution: Up to 111,327,435 shares of Common Stock issuable including all warrants (without beneficial ownership limitations).
- Use of Proceeds: Repayment of outstanding indebtedness, working capital, and general corporate purposes including clinical programs.
Material Changes and Strategic Agreements
- Board Expansion: The Board of Directors increased in size from six to eight members to accommodate designees from Nant Capital, LLC.
- Board Designation Rights: Nant Capital gains the right to designate two board members (including Dr. Patrick Soon-Shiong) if it beneficially owns 15% or more of the outstanding Common Stock.
- Exclusive License Option: The Company granted NantWorks, LLC an exclusive right to negotiate a license for the PDS0101 program for a $25,000 payment, valid for one year.
- Lock-Up Period: The Company is restricted from issuing new equity or filing registration statements for new equity until the shares from this transaction are registered, subject to customary exceptions.
Guidance, Risks, and Contingencies
- Closing Conditions: The Initial Closing is expected on or about September 11, 2026, subject to satisfaction of closing conditions. The agreement may be terminated if the closing does not occur by September 21, 2026.
- Registration Rights: The Company must file a registration statement within 30 days of closing and use best efforts to make it effective within 60 days. Failure to maintain registration effectiveness may result in liquidated damages of up to 5.0% of the purchase price per holder.
- Beneficial Ownership Limitations: Purchasers are subject to a 19.9% beneficial ownership limitation, which may not be waived.
- Forward-Looking Risks: Actual results may differ due to market conditions, satisfaction of closing conditions, and the success of clinical trials required for the Milestone Closing.
Investor Verification Checklist
- Verify the actual closing date and final proceeds received, as the Initial Closing is currently expected but not guaranteed.
- Confirm the appointment of the two Nant Capital designees to the Board of Directors.
- Monitor the status of the Phase 3 clinical trial protocol submission for PDS0301 to determine if the $11M Milestone Closing will be triggered.
- Review the effectiveness of the Form S-3 registration statement for the resale of the newly issued securities.
- Assess the impact of the 111+ million potential shares on existing shareholder dilution.